Kolman Ada
Department of Molecular Biology and Functional Genomics, Stockholm University, SE-106 91 Stockholm, Sweden.
IDrugs. 2003 Aug;6(8):795-801.
Allos Therapeutics Inc is developing the hemoglobin allosteric modifier efaproxiral as a potential radiosensitizer and chemotherapy enhancer in cancer therapy.
阿洛思治疗公司正在研发血红蛋白变构调节剂依氟鸟氨酸,将其作为癌症治疗中一种潜在的放射增敏剂和化疗增强剂。